The company's standalone total income from operations rose 5.18 per cent to Rs 270.03 crore during the quarter under consideration. The company has not disclosed consolidated numbers for the quarter.
ALSO READ: Strides Arcolab acquires Aspen's generics biz in Australia for A$ 380 mn
Commenting on the results, Strides Arcolab Founder and Group CEO Arun Kumar said: "The quality of business and profitability has been hallmark of our FY15 performance. The merger with Shasun Pharma and re-entry into the Australian market will make us a fully-integrated global pharmaceutical company with size and scale."
Meanwhile, Strides has announced that its board has recommended a dividend of Rs 3 per share for year-ended March 31, 2015. Strides Arcolab shares ended up .49 per cent at Rs 1,193.70 on the BSE.